Symbols / INMD Stock $13.82 -0.07% InMode Ltd.

Healthcare • Medical Devices • Israel • NMS
INMD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Moshe Mizrahy
Exch · Country NMS · Israel
Market Cap 840.38M
Enterprise Value 344.51M
Income 87.19M
Sales 374.64M
FCF (ttm) 43.63M
Book/sh 10.78
Cash/sh 8.47
Employees 660
Insider 10d —
IPO Aug 08, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 10.24
Forward P/E 9.36
PEG 0.83
P/S 2.24
P/B 1.28
P/C —
EV/EBITDA 4.28
EV/Sales 0.92
Quick Ratio 7.47
Current Ratio 8.80
Debt/Eq 0.73
LT Debt/Eq —
EPS (ttm) 1.35
EPS next Y 1.48
EPS Growth -30.80%
Revenue Growth 5.30%
EPS Gr Q/Q -36.50%
Rev Gr Q/Q —
Earnings (next) 2026-07-30
Earnings (prior) 2026-05-06
ROA 6.86%
ROE 13.62%
ROIC —
Gross Margin 77.84%
Oper. Margin 12.26%
Profit Margin 23.27%
Shs Outstand 60.81M
Shs Float 54.97M
Insider Own 11.91%
Instit Own 52.98%
Short Float 6.11%
Short Ratio 4.90
Short Interest 3.30M
52W High 16.74
vs 52W High -17.44%
52W Low 12.72
vs 52W Low 8.65%
Beta 1.98
Impl. Vol. 78.13%
Rel Volume 0.37
Avg Volume 905.71K
Volume 330.82K
Target (mean) $15.50
Tgt Median $14.50
Tgt Low $14.00
Tgt High $19.00
# Analysts 4
Recom Hold
Prev Close $13.83
Price $13.82
Change -0.07%
About

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$15.50
Mean price target
2. Current target
$13.82
Latest analyst target
3. DCF / Fair value
$12.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.82
Low
$14.00
High
$19.00
Mean
$15.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-07 main Barclays Overweight → Overweight $19
2026-05-07 main Baird Neutral → Neutral $14
2025-12-17 main Canaccord Genuity Hold → Hold $15
2025-11-06 main UBS Neutral → Neutral $16
2025-10-10 main Canaccord Genuity Hold → Hold $16
2025-10-10 reit Needham Hold → Hold —
2025-07-30 reit Needham Hold → Hold —
2025-07-30 main Barclays Overweight → Overweight $21
2025-07-11 main Canaccord Genuity Hold → Hold $15
2025-04-30 main Barclays Overweight → Overweight $24
2025-04-29 main UBS Neutral → Neutral $16
2025-04-29 down BTIG Buy → Neutral —
2025-04-29 main Canaccord Genuity Hold → Hold $15
2025-04-28 reit Needham Hold → Hold —
2025-04-14 main Jefferies Hold → Hold $15
2025-04-14 reit Needham Hold → Hold —
2025-04-09 reit Needham Hold → Hold —
2025-02-05 main Barclays Overweight → Overweight $29
2025-02-04 main Needham Hold → Hold —
2025-01-09 main Barclays Overweight → Overweight $26
News
RSS: Latest INMD news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
370.50
-6.16%
394.82
-19.76%
492.05
+8.32%
454.27
Operating Revenue
370.50
-6.16%
394.82
-19.76%
492.05
+8.32%
454.27
Cost Of Revenue
79.53
+2.28%
77.75
-3.66%
80.71
+9.83%
73.48
Reconciled Cost Of Revenue
79.53
+2.28%
77.75
-3.66%
80.71
+9.83%
73.48
Gross Profit
290.97
-8.23%
317.07
-22.92%
411.34
+8.02%
380.79
Operating Expense
205.58
+0.51%
204.53
-5.17%
215.68
+17.90%
182.93
Research And Development
13.32
+1.39%
13.14
-2.04%
13.41
+7.93%
12.43
Selling General And Administration
192.26
+0.45%
191.40
-5.37%
202.27
+18.63%
170.51
Selling And Marketing Expense
180.58
-0.43%
181.37
-6.05%
193.04
+20.22%
160.58
General And Administrative Expense
11.69
+16.49%
10.03
+8.71%
9.23
-7.08%
9.93
Other Gand A
11.69
+16.49%
10.03
+8.71%
9.23
-7.08%
9.93
Other Operating Expenses
—
—
—
—
Total Expenses
285.11
+1.00%
282.29
-4.76%
296.39
+15.59%
256.42
Operating Income
85.39
-24.12%
112.53
-42.49%
195.66
-1.11%
197.85
Total Operating Income As Reported
85.39
-24.12%
112.53
-42.49%
195.66
-1.11%
197.85
EBITDA
86.08
-24.00%
113.26
-42.30%
196.28
-1.13%
198.53
Normalized EBITDA
86.08
-24.00%
113.26
-42.30%
196.28
-1.13%
198.53
Reconciled Depreciation
0.69
-4.53%
0.73
+16.85%
0.62
-8.38%
0.68
EBIT
85.39
-24.12%
112.53
-42.49%
195.66
-1.11%
197.85
Net Income
93.83
-48.24%
181.28
-8.41%
197.92
+22.54%
161.52
Pretax Income
110.33
-23.10%
143.47
-33.97%
217.27
+7.84%
201.47
Net Non Operating Interest Income Expense
24.94
-19.38%
30.94
+43.19%
21.61
+498.20%
3.61
Net Interest Income
24.94
-19.38%
30.94
+43.19%
21.61
+498.20%
3.61
Interest Income Non Operating
24.94
-19.38%
30.94
+43.19%
21.61
+498.20%
3.61
Interest Income
24.94
-19.38%
30.94
+43.19%
21.61
+498.20%
3.61
Tax Provision
16.50
+143.64%
-37.81
-295.40%
19.35
-51.56%
39.95
Tax Rate For Calcs
0.00
-23.81%
0.00
+110.00%
0.00
-49.57%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
93.83
-48.24%
181.28
-8.41%
197.92
+22.54%
161.52
Net Income From Continuing Operation Net Minority Interest
93.83
-48.24%
181.28
-8.41%
197.92
+22.54%
161.52
Net Income From Continuing And Discontinued Operation
93.83
-48.24%
181.28
-8.41%
197.92
+22.54%
161.52
Net Income Continuous Operations
93.83
-48.24%
181.28
-8.41%
197.92
+22.54%
161.52
Minority Interests
—
—
0.00
0.00
Normalized Income
93.83
-48.24%
181.28
-8.41%
197.92
+22.54%
161.52
Net Income Common Stockholders
93.83
-48.24%
181.28
-8.41%
197.92
+22.54%
161.52
Diluted EPS
1.43
-36.44%
2.25
-2.17%
2.30
+21.69%
1.89
Basic EPS
1.45
-36.68%
2.29
-3.38%
2.37
+20.92%
1.96
Basic Average Shares
64.63
-18.50%
79.31
-5.06%
83.53
+1.28%
82.48
Diluted Average Shares
65.44
-18.80%
80.60
-6.23%
85.95
+0.64%
85.40
Diluted NI Availto Com Stockholders
93.83
-48.24%
181.28
-8.41%
197.92
+22.54%
161.52
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
766.43
-2.45%
785.67
-8.99%
863.29
+33.97%
644.41
Current Assets
698.62
-2.22%
714.45
-15.48%
845.33
+34.31%
629.37
Cash Cash Equivalents And Short Term Investments
555.33
-6.90%
596.47
-19.57%
741.61
+35.48%
547.38
Cash And Cash Equivalents
302.54
+94.78%
155.33
+7.56%
144.41
+48.05%
97.54
Other Short Term Investments
252.79
-42.70%
441.14
-26.13%
597.19
+32.76%
449.84
Receivables
49.28
+20.05%
41.05
-5.91%
43.63
+54.36%
28.27
Accounts Receivable
43.50
+19.73%
36.34
-14.23%
42.36
+56.91%
27.00
Gross Accounts Receivable
45.88
+20.22%
38.16
-13.08%
43.90
+57.73%
27.83
Allowance For Doubtful Accounts Receivable
-2.37
-29.92%
-1.82
-18.66%
-1.54
-83.97%
-0.84
Other Receivables
1.83
-44.46%
3.29
+174.19%
1.20
-1.88%
1.22
Taxes Receivable
3.95
+177.51%
1.42
+2056.06%
0.07
+50.00%
0.04
Inventory
74.05
+24.35%
59.55
+32.05%
45.09
+13.03%
39.90
Raw Materials
27.19
+75.92%
15.45
+27.93%
12.08
-11.73%
13.69
Finished Goods
46.86
+6.28%
44.09
+33.56%
33.02
+25.96%
26.21
Prepaid Assets
19.95
+14.81%
17.38
+15.87%
15.00
+8.50%
13.83
Total Non Current Assets
67.81
-4.78%
71.22
+296.61%
17.96
+19.40%
15.04
Net PPE
10.87
-1.64%
11.05
-8.49%
12.08
+63.89%
7.37
Gross PPE
15.75
+3.37%
15.24
-1.92%
15.54
+52.25%
10.21
Accumulated Depreciation
-4.88
-16.61%
-4.18
-21.06%
-3.46
-21.98%
-2.83
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.25
+4.55%
2.15
+7.49%
2.00
+14.32%
1.75
Other Properties
12.08
+2.78%
11.75
-4.38%
12.29
+61.22%
7.62
Leases
1.42
+6.68%
1.33
+7.24%
1.24
+49.94%
0.83
Investments And Advances
0.70
+0.00%
0.70
+0.00%
0.70
+16.67%
0.60
Long Term Equity Investment
0.70
+0.00%
0.70
+0.00%
0.70
+16.67%
0.60
Other Investments
—
—
—
—
Non Current Accounts Receivable
3.00
-5.38%
3.18
-13.46%
3.67
-7.63%
3.97
Non Current Deferred Assets
53.23
-5.43%
56.28
+3637.38%
1.51
-51.33%
3.09
Non Current Deferred Taxes Assets
53.23
-5.43%
56.28
+3637.38%
1.51
-51.33%
3.09
Total Liabilities Net Minority Interest
83.23
+1.68%
81.85
+7.82%
75.91
-15.45%
89.79
Current Liabilities
70.74
+1.28%
69.85
+8.91%
64.14
-21.80%
82.02
Payables And Accrued Expenses
20.38
+19.24%
17.09
-1.30%
17.32
-51.19%
35.48
Payables
18.67
+26.90%
14.71
-7.36%
15.88
-55.23%
35.48
Accounts Payable
17.91
+29.97%
13.78
-1.32%
13.97
-14.01%
16.24
Current Accrued Expenses
1.71
-28.12%
2.38
+65.78%
1.44
—
Pensionand Other Post Retirement Benefit Plans Current
18.16
+8.56%
16.73
-20.51%
21.04
+8.24%
19.44
Total Tax Payable
0.76
-18.44%
0.93
-51.36%
1.92
-90.03%
19.24
Income Tax Payable
0.76
-18.44%
0.93
-51.36%
1.92
-90.03%
19.24
Current Debt And Capital Lease Obligation
3.22
+28.20%
2.51
+4.45%
2.40
+65.45%
1.45
Current Capital Lease Obligation
3.22
+28.20%
2.51
+4.45%
2.40
+65.45%
1.45
Current Deferred Liabilities
12.09
-27.82%
16.75
+53.39%
10.92
-20.84%
13.80
Current Deferred Revenue
12.09
-27.82%
16.75
+53.39%
10.92
-20.84%
13.80
Other Current Liabilities
15.96
-0.52%
16.04
+46.20%
10.97
+5.23%
10.43
Total Non Current Liabilities Net Minority Interest
12.49
+4.03%
12.00
+1.91%
11.78
+51.56%
7.77
Long Term Debt And Capital Lease Obligation
5.01
-5.71%
5.31
-19.69%
6.61
+88.46%
3.51
Long Term Capital Lease Obligation
5.01
-5.71%
5.31
-19.69%
6.61
+88.46%
3.51
Non Current Deferred Liabilities
3.04
-8.78%
3.34
-11.42%
3.77
-4.87%
3.96
Non Current Deferred Revenue
3.04
-8.78%
3.34
-11.42%
3.77
-4.87%
3.96
Other Non Current Liabilities
4.44
+32.18%
3.36
+139.89%
1.40
+361.72%
0.30
Stockholders Equity
683.20
-2.93%
703.81
-10.61%
787.37
+41.97%
554.62
Common Stock Equity
683.20
-2.93%
703.81
-10.61%
787.37
+41.97%
554.62
Capital Stock
0.25
+0.80%
0.25
+1.63%
0.24
+1.66%
0.24
Common Stock
0.25
+0.80%
0.25
+1.63%
0.24
+1.66%
0.24
Share Issued
88.33
+0.86%
87.58
+1.89%
85.96
+1.70%
84.52
Ordinary Shares Number
63.36
-8.91%
69.56
-17.17%
83.98
+1.74%
82.54
Treasury Shares Number
24.98
+38.56%
18.03
+812.66%
1.98
+0.00%
1.98
Additional Paid In Capital
209.62
+6.39%
197.03
+10.80%
177.82
+19.50%
148.80
Retained Earnings
968.53
+10.73%
874.70
+26.14%
693.43
+39.94%
495.51
Gains Losses Not Affecting Retained Earnings
0.07
+120.29%
-0.34
+79.75%
-1.68
+77.59%
-7.49
Treasury Stock
495.27
+34.65%
367.82
+346.17%
82.44
+0.00%
82.44
Minority Interest
—
—
—
0.00
Total Equity Gross Minority Interest
683.20
-2.93%
703.81
-10.61%
787.37
+41.97%
554.62
Total Capitalization
683.20
-2.93%
703.81
-10.61%
787.37
+41.97%
554.62
Working Capital
627.88
-2.59%
644.60
-17.49%
781.19
+42.72%
547.35
Invested Capital
683.20
-2.93%
703.81
-10.61%
787.37
+41.97%
554.62
Total Debt
8.23
+5.18%
7.82
-13.25%
9.02
+81.72%
4.96
Capital Lease Obligations
8.23
+5.18%
7.82
-13.25%
9.02
+81.72%
4.96
Net Tangible Assets
683.20
-2.93%
703.81
-10.61%
787.37
+41.97%
554.62
Tangible Book Value
683.20
-2.93%
703.81
-10.61%
787.37
+41.97%
554.62
Current Provisions
0.93
+28.95%
0.72
-51.08%
1.48
+4.09%
1.42
Investments In Other Ventures Under Equity Method
0.70
+0.00%
0.70
+0.00%
0.70
+16.67%
0.60
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
85.26
-35.73%
132.66
-24.97%
176.83
-2.62%
181.58
Cash Flow From Continuing Operating Activities
85.26
-35.73%
132.66
-24.97%
176.83
-2.62%
181.58
Net Income From Continuing Operations
93.83
-48.24%
181.28
-8.41%
197.92
+22.54%
161.52
Depreciation Amortization Depletion
0.69
-4.53%
0.73
+16.85%
0.62
-8.38%
0.68
Depreciation
0.69
-4.53%
0.73
+16.85%
0.62
-8.38%
0.68
Depreciation And Amortization
0.69
-4.53%
0.73
+16.85%
0.62
-8.38%
0.68
Other Non Cash Items
0.50
+111.32%
-4.40
+6.64%
-4.71
-289.59%
-1.21
Stock Based Compensation
11.13
-32.82%
16.57
-29.79%
23.60
-3.48%
24.45
Provisionand Write Offof Assets
0.45
-20.63%
0.57
-43.92%
1.02
+127.17%
0.45
Deferred Tax
2.93
+105.31%
-55.18
-29888.59%
-0.18
-319.05%
0.08
Deferred Income Tax
2.93
+105.31%
-55.18
-29888.59%
-0.18
-319.05%
0.08
Operating Gains Losses
0.01
-91.02%
0.17
—
0.07
Gain Loss On Investment Securities
0.01
-91.02%
0.17
—
0.07
Change In Working Capital
-24.30
-243.78%
-7.07
+82.95%
-41.44
-827.44%
-4.47
Change In Receivables
-11.13
-4534.26%
0.25
+101.37%
-18.31
-50.04%
-12.20
Changes In Account Receivables
-7.45
-225.26%
5.95
+136.99%
-16.08
-54.43%
-10.41
Change In Inventory
-14.50
-0.34%
-14.45
-178.05%
-5.20
+72.46%
-18.87
Change In Payables And Accrued Expense
4.13
+2344.02%
-0.18
+91.92%
-2.28
-130.50%
7.46
Change In Accrued Expense
—
—
—
—
Change In Payable
4.13
+2344.02%
-0.18
+91.92%
-2.28
-130.50%
7.46
Change In Account Payable
4.13
+2344.02%
-0.18
+91.92%
-2.28
-130.50%
7.46
Change In Other Working Capital
-4.96
-191.73%
5.40
+276.08%
-3.07
-355.45%
1.20
Change In Other Current Liabilities
2.16
+12.83%
1.92
+115.23%
-12.59
-170.16%
17.94
Investing Cash Flow
186.03
+14.69%
162.21
+219.21%
-136.06
-24.29%
-109.47
Cash Flow From Continuing Investing Activities
186.03
+14.69%
162.21
+219.21%
-136.06
-24.29%
-109.47
Net PPE Purchase And Sale
-0.97
-45.29%
-0.67
+5.11%
-0.70
+55.24%
-1.57
Purchase Of PPE
-0.97
-45.29%
-0.67
+5.11%
-0.70
+55.24%
-1.57
Capital Expenditure
-0.97
-45.29%
-0.67
+5.11%
-0.70
+55.24%
-1.57
Net Investment Purchase And Sale
187.00
+14.81%
162.88
+220.33%
-135.36
-25.45%
-107.90
Purchase Of Investment
-313.51
+37.85%
-504.41
-5.38%
-478.68
-82.44%
-262.38
Sale Of Investment
500.52
-24.99%
667.28
+94.36%
343.32
+122.24%
154.48
Financing Cash Flow
-126.06
+55.42%
-282.77
-5237.55%
5.50
+113.40%
-41.09
Cash Flow From Continuing Financing Activities
-126.06
+55.42%
-282.77
-5237.55%
5.50
+113.40%
-41.09
Net Common Stock Issuance
-127.44
+55.34%
-285.38
0.00
+100.00%
-42.64
Common Stock Payments
-127.44
+55.34%
-285.38
0.00
+100.00%
-42.64
Repurchase Of Capital Stock
-127.44
+55.34%
-285.38
0.00
+100.00%
-42.64
Proceeds From Stock Option Exercised
1.39
-47.02%
2.61
-52.51%
5.50
+254.64%
1.55
Changes In Cash
145.23
+1100.35%
12.10
-73.85%
46.27
+49.15%
31.02
Effect Of Exchange Rate Changes
1.98
+267.99%
-1.18
-295.21%
0.60
+137.46%
-1.61
Beginning Cash Position
155.33
+7.56%
144.41
+48.05%
97.54
+43.15%
68.14
End Cash Position
302.54
+94.78%
155.33
+7.56%
144.41
+48.05%
97.54
Free Cash Flow
84.28
-36.15%
132.00
-25.05%
176.12
-2.16%
180.00
Income Tax Paid Supplemental Data
14.87
-15.96%
17.69
-44.04%
31.61
+22.33%
25.84
Common Stock Issuance
—
—
—
—
Issuance Of Capital Stock
—
—
—
—
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category